GammaCan Executes Supply Agreement with Bio Products Laboratory to Manufacture VitiGam(TM) for the Treatment of Melanoma for Cli

  
    
  
  
    
      GammaCan International, Inc. (“GammaCan” 
      or “the Company”) 
      (OTCBB:GCAN) a developer of proprietary immunotherapies for the 
      treatment of melanoma and other cancers, today announced that the Company’s 
      subsidiary has entered into a comprehensive manufacturing agreement with 
      Bio Products Laboratory ("BPL") to produce the Company’s 
      lead drug candidate, VitiGam™, from plasma 
      derived from Vitiligo donors. BPL is a division of National Health 
      Service Blood and Transplant, a unit of the United Kingdom National 
      Health Service. BPL is a leading manufacturer of plasma-based products 
      distributed worldwide.
    
    
      Under the terms of agreement, BPL will manufacture VitiGam™ 
      utilizing its proprietary GAMMAPLEX process. The multi-year agreement 
      provides for the supply to GammaCan of VitiGam™ 
      for the Company's immediate clinical testing needs and for future 
      commercial sale. In addition, the agreement provides that BPL will 
      provide the Company with technical, scientific and other data, including 
      specific support for its U.S. regulatory filings and future regulatory 
      approvals in other markets. While specific financial terms will not be 
      disclosed, the agreement provides that BPL will produce VitiGam™ 
      for clinical testing and future commercial sale at market-based prices. 
      The Company will purchase related services, when required, also at 
      agreed upon and market-based pricing.
    
    
      Steven Katz, Chairman of the Board and President of GammaCan said, "Our 
      ability to enter into a supply contract with a market leader such as BPL 
      constitutes further validation of our technology. Securing a 
      manufacturer of VitiGam™ for our clinical 
      testing program is also one of the last major steps needed to assure our 
      ability to submit an IND with the U.S. FDA in the near-term."
    
    
      Andrew Williams, Sales and Marketing Director for BPL, commented, 
      "GammaCan's manufacturing requirements can be readily integrated with 
      our capabilities. This new relationship with GammaCan will enable us to 
      participate, at an early stage, in a most promising and exciting 
      commercial opportunity."
    
    
      About GammaCan
    
    
      GammaCan develops proprietary immunotherapy and related approaches to 
      treat melanoma and other cancers. GammaCan's patented platform 
      technology is based on the use of IgGs (gamma-immunoglobulins), a safe, 
      relatively non-toxic human plasma-derived product used to treat a 
      variety of immune deficiencies and autoimmune diseases. In cancer, 
      IgG-based therapies work by strengthening the patient's immune system. 
      Many experts currently view immunotherapy as a future alternative to 
      chemotherapy. The Company's lead drug candidate, VitiGam™, 
      targets Stage III and Stage IV melanoma for which no effective treatment 
      currently exists. In August 2007, VitiGam™ 
      received Orphan Drug designation from the U.S. Food and Drug 
      Administration (FDA) for the treatment of Stage IIB to Stage IV 
      metastatic melanoma. For more information about GammaCan, visit www.GammaCan.com.
    
    
      About BPL
    
    
      BPL is located in Elstree on the outskirts of London. BPL processes 
      human plasma (sourced from U.S. donors) through to a range of highly 
      purified and safe plasma products, including intravenous immunoglobulin 
      (IVIG), albumin, Factor VIII and Factor IX. BPL invests in the latest 
      research, technology and manufacturing methods and is committed to 
      provide a continuous and competitive supply of high quality 
      plasma-derived products to the United Kingdom and a growing global 
      market. For more information about BPL, visit www.bpl.co.uk.
    
    
      About VitiGam™
    
    
      VitiGam™ is a first-in-class IgG-based 
      anti-cancer immunotherapy being developed for the treatment of Stage III 
      and Stage IV melanoma. GammaCan is planning to submit its 
      Investigational New Drug Application (IND) for VitiGam™ 
      to the FDA in the near future. The Company expects to commence human 
      clinical trials shortly thereafter. VitiGam™ 
      is an IgG-based product manufactured from the plasma of donors with 
      Vitiligo, a benign skin condition affecting up to 2% of the general 
      population. Studies have shown that this "enriched" IgG formulation 
      contains potent anti-melanoma activity. Based on these studies, GammaCan 
      expects VitiGam™ to provide specific 
      anti-melanoma activity against melanoma cells, as well as non-specific 
      anti-cancer activity.
    
    
      About Melanoma
    
    
      Melanoma is a deadly form of skin cancer. According to the American 
      Cancer Society, melanoma accounts for approximately 4% of all skin 
      cancers but causes approximately 75% of all skin cancer-related deaths. 
      An estimated 62,000 people were diagnosed with and nearly 8,000 people 
      died from melanoma in the U.S. alone in 2007. If rapidly diagnosed and 
      surgically removed, early-stage melanoma is usually curable. However, 
      for patients with metastatic melanoma (Stage III and Stage IV), the 
      prognosis is poor since no effective treatment currently exists. These 
      patients have a median survival time of 8.5 months and a 5-year survival 
      rate of less than 10%. There has been little change in these results for 
      in excess of 25 years. The incidence of melanoma has increased more 
      rapidly than any other cancer during the past 10 years. The last drug to 
      treat patients with metastatic melanoma was approved by the FDA over 30 
      years ago.
    
    
      Safe Harbor Statement
    
    
      Statements in this press release that are not purely historical are 
      forward-looking statements. Forward-looking statements in this press 
      release include statements regarding: the commercialization of 
      anti-cancer immunotherapies and the Company's efforts to develop 
      therapies to boost the immune systems of cancer patients by the use of 
      IgG-based therapy. Actual outcomes and the Company's actual results 
      could differ materially from those in such forward-looking statements. 
      Factors that could cause actual results to differ materially include 
      risks and uncertainties such as the inability to finance the planned 
      development of the technology; the inability to hire appropriate staff 
      to develop the technology; unforeseen technical difficulties in 
      developing the technology; the inability to obtain regulatory approval 
      for human use; competitors' therapies proving to be more effective, 
      cheaper or otherwise preferable for consumers; the inability to market a 
      product; all of which could, among other things, delay or prevent 
      product release, as well as other factors expressed from time to time in 
      GammaCan's periodic filings with the Securities and Exchange Commission 
      (the "SEC"). As a result, this press release should be read in 
      conjunction with GammaCan's periodic filings with the SEC, which are 
      incorporated herein by reference. The forward-looking statements 
      contained herein are made only as of the date of this press release and 
      GammaCan undertakes no obligation to publicly update such 
      forward-looking statements to reflect subsequent events or circumstances.